Special Issues

Ask the Expert: COMMANDS Trial Results of First-Line Luspatercept Versus Epoetin Alfa in Transfusion-Dependent Patients With Lower-Risk Myelodysplastic Syndromes

By Amer Zeidan, MBBS, MHS

Supplements

2022 Year in Review - Multiple Myeloma

Supplements

Best Practices: Education for Patients with Advanced NSCLC Treated with Immune Checkpoint Inhibitors

By Marianne Davies, DNP, ACNP, AOCNP, FAAN; Shawn Perkins, RN, BSN, OCN

Supplements

2022 Year in Review - Cholangiocarcinoma

Supplements

Best Practices: Immune-Related Adverse Event Management in Patients with Advanced NSCLC Treated with Immune Checkpoint Inhibitors

By Amanda L. Brink, DNP, APRN, FNP-BC, AOCNP; Aung Naing, MD, FACP

Supplements

Best Practices: Biomarkers and Treatment Selection in the Management of Advanced NSCLC

By Wallace Akerley, MD; Katie Kerrigan, DO

Supplements

2022 Midyear Review: Non–Small-Cell Lung Cancer

Lung Cancer

Supplements

First-Line OPDIVO® (nivolumab) in Combination with Chemotherapy in Patients with Advanced or Metastatic Gastric Cancer, Gastroesophageal Cancer, and Esophageal Adenocarcinoma

Supplements

Best Practices: Practical Guidance in Treating Advanced NSCLC with Immunotherapy

By Jonathan Wesley Riess, MD, MS

NSCLC

Supplements

Lung cancer is the second-most common type of cancer in the United States, including approximately 235,000 new cases each year, 84% of which are non–small-cell lung cancer (NSCLC). Read More ›

Best Practices in Multiple Myeloma: Improving Adherence to Optimize Patient Outcomes

Multiple Myeloma

Supplements

Page 1 of 7

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

TON Print Edition

TON Weekly e‑Newsletter

Special Issues

Page 1 of 7

View the Latest Issue of TON

Subscribe Today!

I'd like to receive: